Effectiveness of second generation antipsychotics: A systematic review of randomized trials by Johnsen, Erik & Jørgensen, Hugo A
BioMed  Central
Page 1 of 14
(page number not for citation purposes)
BMC Psychiatry
Open Access Research article
Effectiveness of second generation antipsychotics: A systematic 
review of randomized trials
Erik Johnsen*1 and Hugo A Jørgensen1,2
Address: 1Haukeland University Hospital, Division of Psychiatry, Sandviken, P.O.Box 23, N-5812, Bergen, Norway and 2Department of Clinical 
Medicine, Section Psychiatry, University of Bergen, N-5020 Bergen, Norway
Email: Erik Johnsen* - erij@ihelse.net; Hugo A Jørgensen - hugo.jorgensen@psyk.uib.no
* Corresponding author    
Abstract
Background: Systematic reviews based on efficacy trials are inconclusive about which second
generation antipsychotic drug (SGA) should be preferred in normal clinical practice, and studies
with longer duration and more pragmatic designs are called for. Effectiveness studies, also known
as naturalistic, pragmatic, practical or real life studies, adhere to these principles as they aim to
mimic daily clinical practice and have longer follow-up.
Objective: To review the head-to-head effectiveness of SGAs in the domains of global outcomes,
symptoms of disease, and tolerability.
Methods:  Searches were made in Embase, PubMED, and the Cochrane central register of
controlled trials for effectiveness studies published from 1980 to 2008, week 1. Different
combinations of the keywords antipsychotic*, neuroleptic* AND open, pragmatic, practical, naturalistic,
real life, effectiveness, side effect*, unwanted effect*, tolera* AND compar* AND random* were used.
Results: Sixteen different reports of randomized head-to-head comparisons of SGA effectiveness
were located. There were differences regarding sample sizes, inclusion criteria and follow-up
periods, as well as sources of financial sponsorship. In acute-phase and first-episode patients no
differences between the SGAs were disclosed regarding alleviating symptoms of disease.
Olanzapine was associated with more weight gain and adverse effects on serum lipids. In the
chronic phase patients olanzapine groups had longer time to discontinuation of treatment and
better treatment adherence compared to other SGAs. The majority of studies found no differences
between the SGAs in alleviating symptoms of psychosis in chronically ill patients. Olanzapine was
associated with more metabolic adverse effects compared to the others SGAs. There were
surprisingly few between-drug differences regarding side effects. First generation antipsychotics
were associated with lower total mental health care costs in 2 of 3 studies on chronically ill patients,
but were also associated with more extrapyramidal side effects compared to the SGAs in several
studies.
Conclusion:  In chronically ill patients olanzapine may have an advantage over other SGAs
regarding longer time to treatment discontinuation and better drug adherence, but the drug is also
associated with more metabolic side effects. More effectiveness studies on first-episode psychosis
are needed.
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Background
Results from effectiveness trials on antipsychotics have
been awaited with anticipation. Several ongoing or
recently completed effectiveness studies in both the USA
and Europe have been expected to supplement the base
of evidence regarding the clinical use of antipsychotic
drugs. According to present international recommenda-
tions most second generation antipsychotics (SGAs)
other than clozapine are considered first line drugs for a
patient suffering from psychosis [1-4]. Despite differing
chemical and pharmacological properties double-blind,
randomized, controlled clinical trials (RCTs) fail to con-
sistently demonstrate superiority for any of these drugs
on efficacy measures. This is reflected in the inconclu-
siveness of systematic reviews on antipsychotics which
call for longer-term trials with more pragmatic designs
[5-12]. RCTs of efficacy are indeed important for new
candidate antipsychotics in establishing superiority over
placebo and/or non-inferiority compared to reference
antipsychotics. Several methodological issues concern-
ing sample selection and the rigid experimental environ-
ment could restrict the generalizability of the efficacy
trial results, however. Selection bias for one is a major
concern. The proportion actually included in the studies
are in many instances difficult to quantify, as the
number of patients initially assessed for eligibility rarely
is disclosed in the scientific papers. Where reported,
however, this proportion in different studies is found to
be as low as 7–27% [13-16]. Then the results from effi-
cacy trials are extrapolated to clinical populations that
may have different characteristics. Adding to this,
patients in normal clinical practice commonly use more
than one psychotropic drug [17-20]. As to what extent
these combinations will modulate the antipsychotic
drug effects and tolerability outcomes registered in RCTs
of efficacy remains to be answered.
The trials of effectiveness have been launched in recent
years to address some of the limitations of efficacy trials.
Effectiveness trials, as opposed to efficacy trials, take a
more pragmatic approach, and could be a rational
approach to the problems related to selection and exper-
imental settings. The trial design is also frequently
labelled "naturalistic", "real-life", "pragmatic", or "prac-
tical". These terms are not strictly defined, but the com-
mon denominator is that both sample and experimental
environment should resemble daily clinical practice. The
core question of effectiveness trials is how a treatment
works under normal clinical circumstances, not in the
ideal situations in the efficacy setting [21]. Another
important feature of effectiveness trials is that outcome
measures also include more global aspects of patient
functioning, such as quality of life measures. Nasrallah
et al. [22] propose a model where effectiveness is meas-
ured according to four domains: Symptoms of disease,
treatment burden, disease burden, and health and well-
ness. Using a modified, 3-domain version of the effec-
tiveness definition proposed by Nasrallah et al., the aims
of the review were to investigate whether effectiveness
trials have disclosed differences between SGAs in the
domains of global outcomes, symptoms of disease, and
how between-drug differences in adverse effect profiles
are expressed in naturalistic settings.
Objective
To review the head-to-head effectiveness of SGAs in the
domains of global outcomes, symptoms of disease, and
tolerability.
Methods
Types of studies
All relevant original randomized, controlled clinical effec-
tiveness trials with head-to-head comparisons of second
generation antipsychotics were eligible for inclusion. Tri-
als were categorized as effectiveness studies if there was a
statement from the authors that a naturalistic, pragmatic,
practical, or real life study design was used, or if the meth-
odology section was presented in corresponding terms.
Studies that restricted the use of concomitant medications
were excluded. In every day clinical practice, adjunctive
psychoactive medications such as antidepressants and
mood stabilizers are commonly used concomitantly with
antipsychotics. This practice is in many instances in
accordance with treatment guidelines [1,23]. Exclusion
from studies of patients that qualify for adjunctive antide-
pressants or mood stabilizers, or restricting them from
using these drugs, are in the opinion of the authors in con-
flict with the pragmatic principle of effectiveness studies.
Only restrictions on the use of more than one antipsy-
chotic drug were tolerated. Conference abstracts were
excluded. Clozapine trials were excluded as this agent is
commonly not regarded a first-line treatment option.
Types of participants
Adult patients (over 16 years of age) with a diagnosis of
schizophrenia or schizophrenia like disorder such as delu-
sional disorder, schizoaffective disorder, schizophreni-
form psychosis.
Types of intervention
1. First line second generation antipsychotic drugs: arip-
iprazole, olanzapine, quetiapine, risperidone, ziprasi-
done.
2. First generation antipsychotic drugs: chlorpromazine,
haloperidole, perphenazine (when included as compara-
tors in head-to-head comparisons of first line second gen-
eration antipsychotic drug).BMC Psychiatry 2008, 8:31 http://www.biomedcentral.com/1471-244X/8/31
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3. Placebo (when included as a comparator group in
head-to-head comparisons of first line second generation
antipsychotic drug).
Types of outcome measures
1. Global outcomes
1.1 Time until discontinuation of assigned antipsychotic
drug for any and specific causes.
1.2 Compliance with assigned antipsychotic drug.
1.3 Duration of hospitalisation.
1.4 Total mental health treatment costs.
1.5 Quality of life – as defined by each of the studies.
2. Symptoms of disease
2.1 Average score/change in mental state – as defined by
each of the studies.
3. Tolerability
3.1 Extrapyramidal side effects.
3.2 Metabolic side effects.
3.3 Prolactin related symptoms.
3.4 Other adverse effects, general and specific.
4. Concomitant medication
4.1 Incidence of antidepressants, antiparkinson drugs,
mood stabilizers, sedatives.
Search strategy for identification of studies
1. Electronic searching
Searches were made in Embase, PubMED and the
Cochrane central register of controlled trials for articles
published from 1980 to 2008, week 1 using the phrase:
[(unwanted effect* AND compar* AND antipsychotic*
AND random*) OR (unwanted effect* AND compar*
AND neuroleptic* AND random*) OR (side effect* AND
compar* AND neuroleptic* AND random*) OR (side
effect* AND compar* AND antipsychotic* AND ran-
dom*) OR (tolera* AND compar* AND neuroleptic*
AND random*) OR (tolera* AND compar* AND antipsy-
chotic* AND random*) OR (efficacy AND compar* AND
neuroleptic* AND random*) OR (efficacy AND compar*
AND antipsychotic* AND random*) OR (pragmatic AND
antipsychotic* AND random*) OR (pragmatic AND neu-
roleptic* AND random*) OR (real life AND neuroleptic*
AND random*) OR (real life AND antipsychotic* AND
random*) OR (naturalistic AND antipsychotic* AND ran-
dom*) OR (naturalistic AND neuroleptic* AND ran-
dom*) OR (open AND neuroleptic* AND random*) OR
(open AND antipsychotic* AND random*) NOT (antip-
sychotic* AND tourette*) NOT (neuroleptic* AND
tourette*) NOT (neuroleptic* AND mania) NOT (antip-
sychotic* AND mania)].
2. Reference searching
The references of all identified studies were inspected for
more trials.
Methods of the review
1. Selection of trials
All citations were inspected by the principal reviewer (EJ).
Studies were selected on the basis of abstracts, and in cases
of doubt, the full text articles were consulted. If doubt
remained, this was resolved by discussion with HAJ.
2. Data collection
Data were extracted from both text and tables of the orig-
inal papers.
3. Data synthesis
3.1 Data presentation
Data on effectiveness was evaluated and grouped accord-
ing to the three domains: global outcomes, symptoms of
disease, and tolerability.
Outcomes were compared between the treatment groups
and graded according to statistically significant inferiority
(<), statistically significant superiority (>), or equality (=)
between groups. Level of significance was set at 0.05.
3.2 Sensitivity analyses
3.2.1 First episode
Results from those experiencing their first episode of psy-
chosis are analyzed separately.
3.2.2 Intention to treat analyses
When result gained from both intention to treat analyses
(ITT) and observed cases (OC) are available, both are
included. P-values are only given for ITT analyses if the
results of both ITT and OC analyses are statistically signif-
icant.
4. Heterogeneity
Results from different trials are analyzed separately
because of study heterogeneity.
5. Addressing funding bias
The funding parties of the studies were registered, as the
matter of conflict of interest in research has become a
growing concern in recent years.BMC Psychiatry 2008, 8:31 http://www.biomedcentral.com/1471-244X/8/31
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Results
Description of studies
The search provided more than a thousand different hits
in the databases, of which the vast majority were non-rel-
evant, animal studies or studies on efficacy. A total of 16
different reports from 10 randomized trials of effective-
ness with head-to-head comparisons of SGAs were
located. The methodological aspects of the trials are pre-
sented in Table 1. Five studies present data from different
phases of the Clinical Antipsychotic Trials of Intervention
Effectiveness (CATIE) [31,35-38]. The studies by Ritchie et
al. [33,34] include elderly patients exclusively, as opposed
to the others. The study sample is the same in the two
studies by Ritchie et al., but the studies present data from
different phases of the same trial. There are differences
across all studies concerning source of sample recruitment
(in- or outpatients), phase of illness (first episode or
chronic), antipsychotic drug doses, and level of diagnostic
specificity in the inclusion criteria. The study by McEvoy
et al. [25] and the CATIE studies applied double-blinding,
the studies by Robinson et al. [26] and McCue et al. [29]
had rater-blinding, whereas the rest were without blind-
ing.
Global outcomes
Table 2 gives an overview of global outcomes. The most
consistent difference is that chronic patients treated with
olanzapine used this antipsychotic drug for a longer time
or with better adherence compared to the other SGAs
[30,31,36,37,39]. Regarding total mental health treat-
ment costs, two studies found significantly lower costs
using FGAs compared to SGAs [30,35], whereas one study
found the total costs to be equal across the drug genera-
tions [38]. Costs were only estimated in chronic-phase
studies.
In first episode patients the comparators performed
equally.
Symptoms of disease
Regarding symptoms of disease (Table 3) the studies on
acute-phase patients including first-episode patients dis-
closed no differences between comparator drugs in the
clinical global impression [24,25]; overall symptoms of
psychosis [24-27,29], depression or mania [24]. In one
study comparing olanzapine and risperidone in first-epi-
sode patients the response seemed to be more stable in
the risperidone group, as measured by the Schedule for
Affective Disorders and Schizophrenia Change Version
with psychosis and disorganization items (SADS-C+PD)
and the Clinical Global Impression scale (CGI) [26]. In
chronic patients the results were less uniform. The major-
ity of the studies found the SGAs to be equally effective for
symptoms of psychosis [30-35,37]. Olanzapine was more
effective for symptoms of psychosis compared to quetiap-
ine and ziprasidone as measured by PANSS in one study
[36]. In one study quetiapine was significantly more effec-
tive for symptoms of depression compared to risperidone
as measured by the Hamilton Rating Scale for Depression
(HAM-D) [32], whereas olanzapine and risperidone was
equally effective on this outcome measure in 3 studies
[30,33,34]. No differences between the SGAs were dis-
closed on the CGI scale.
Tolerability
Concerning the tolerability outcomes (Table 4) the most
consistent differences between the SGAs were more
weight gain and adverse effects on serum lipids in the
olanzapine treated groups. This was found in both acute
phase including first-episode patients and chronically ill
patients [24-27,31,36,37,39]. Only one study comparing
olanzapine and risperidone in the elderly found no signif-
icant difference between the drugs with regards to weight
gain [34]. Regarding sexual dysfunction and related symp-
toms only one study used this outcome measure in the
acute phase trials and found no difference between
haloperidol, olanzapine and risperidone. In the studies
including chronic patients no differences between olanza-
pine, quetiapine, risperidone and ziprasidone were found
in one study on this outcome measure despite signifi-
cantly higher mean prolactin change in the risperidone
group compared to the others [31], and no difference was
found between olanzapine and risperidone in the elderly
[34]. Risperidone was associated with more sexual dys-
functions and gynecomastia/galactorrhoea compared to
olanzapine, quetiapine and ziprasidone in CATIE patients
who had previously discontinued previous treatment with
an SGA [36]; whereas olanzapine, quetiapine and risperi-
done were equally associated with sexual dysfunctions in
those who had previously discontinued perphenazine
[37]. In both the latter studies risperidone treated groups
had more prolactin elevation than the other SGAs. The
incidence of extrapyramidal symptoms (EPS) were
equally distributed among the comparator SGA groups
across all studies using this outcome measure, whereas the
FGAs were associated with significantly more EPS or dis-
continuation owing to EPS in 3 [24,31,39] of 5 studies,
whereas 2 studies did not find EPS differences between
FGAs and SGAs [29,30]. The last study including an FGA
arm did not have outcomes on this measure.
Concomitant medication
On the use of concomitant medications (Table 5) there
were no consistent differences between the SGAs.
Funding
Six studies were supported by pharmaceutical companies.
Reported findings of differences between comparator
SGAs were in favour of the supporter's drugs in 5 of theseBMC Psychiatry 2008, 8:31 http://www.biomedcentral.com/1471-244X/8/31
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Table 1: Methodology
Study Comparators Doses (DDD) Diagnoses Age Phase/status N0/Nitt/N1 Follow-up Funding
FIRST 
EPISODE
Crespo-
Facorro et 
al. [24]
Haloperidol
Olanzapine
Risperidone
5.4 mg (0.68)
15.3 mg (1.53)
4.0 mg (0.80)
Schizophrenia 
and related, 
non-affective 
psychosis
15–60 years Acute, first episode in- 
and outpatients
172/172/165 6 weeks Independent
McEvoy et al. 
[25]
Olanzapine
Quetiapine
Risperidone
11.7 mg (1.17)
506.0 mg (1.27)
2.4 mg (0.5)
Schizophrenia, 
schizoaffective- 
schizophrenifor
m disorder
16–40 years Acute, first episode in- 
and outpatients
400/-/119 12 months AstraZeneca 
company
Robinson et 
al. [26]
Olanzapine
Risperidone
11.8 mg (1.18)
3.9 mg (0.78)
Schizophrenia, 
schizoaffective- 
schizophrenifor
m disorder
16–40 years Acute, first episode 120/112/81 4 months Independent
ACUTE 
PHASE
Chrzanowski 
et al. [27]
Aripiprazole
Olanzapine
22.0 mg (1.47)
14.2 mg (1.42)
Schizophrenia ≥ 18 years Acute psychosis/chronic 
stable in- and outpatients
214/214/147 52 weeks BMS/Otsuka
Kraus et al. 
[28]
Olanzapine
Risperidone
12.4 mg (1.24)
3.4 mg (0.39)
Psychosis; 
positive 
symptoms
18–60 years Acute, inpatients 85/-/68 Not defined Independent
McCue et al. 
[29]
Aripiprazole
Haloperidol
Olanzapine 
Quetiapine 
Risperidone 
Ziprasidone
21.8 mg1 (1.45)
16.0 mg 1(2.00)
19.1 mg 1(1.91)
652.5 mg1 (1.63)
5.2 mg1 (1.04)
151.2 mg1 (1.89)
Schizophrenia, 
schizoaffective- 
schizophrenifor
m disorder
≥ 18 years Acute, inpatients 327/319/301 3 weeks Independent
CHRONIC 
PHASE
Jerrel [30] Olanzapine
Risperidone
Haloperidol
Haloperidol (d)
Fluphenazine (d)
13.8 mg (1.38)
5.3 mg (1.06)
15.5 mg (1.93)
6.3 mg (1.92)
3.0 mg (0.43)
Schizophrenia 
and 
schizoaffective 
disorder
18–54 years Chronic, inpatients acute 
care
108/-/84 12 months Independent
Lieberman et 
al. [31]
Olanzapine
Perphenazine
Quetiapine
Risperidone
Ziprasidone
20.1 mg (2.01)
20.8 mg (0.69)
543.4 mg (1.36)
3.9 mg (0.78)
112.8 mg (1.41)
Schizophrenia 18–65 years Chronic, not treatment 
resistant, in- and 
outpatients
1493/1432/371 18 months Independent
Mullen et al. 
[32]
Quetiapine
Risperidone
329.0 mg (0.82)
5.0 mg (1.00)
Psychotic 
disorders2
> 18 years Outpatients 728/-/493 4 months AstraZeneca 
company
Ritchie et al. 
[33]
Olanzapine
Risperidone
9.9 mg (0.99)
1.7 mg (0.34)
Schizophrenia > 60 years Outpatients, switch from 
FGAs
66/61/52 switch period 
(mean 40 
days)
Eli Lilly 
company
Ritchie et al. 
[34]
Olanzapine
Risperidone
12.4 mg (1.24)
2.0 mg (0.39)
Schizophrenia > 60 years Outpatients, switch from 
FGAs
66/61/42 6 months Eli Lilly 
company
Rosenheck 
et al. [35]
Olanzapine
Perphenazine
Quetiapine
Risperidone
Ziprasidone
Not disclosed
-
-
-
-
Schizophrenia 18–65 years Chronic, not treatment 
resistant, in- and 
outpatients
1493/1424/363 18 months Independent
Stroup et al. 
[36]
Olanzapine
Quetiapine
Risperidone
Ziprasidone
20.5 mg (2.05)
565.2 mg (1.41)
4.1 mg (0.82)
115.9 mg (1.45)
Schizophrenia 18–65 years Chronic, not treatment 
resistant, in- and 
outpatients, discontinued 
previous SGA because of 
intolerability
444/333/88 18 months Independent
Stroup et al. 
[37]
Olanzapine
Quetiapine
Risperidone
20.7 mg (2.07)
586.1 mg (1.47)
3.7 mg (0.74)
Schizophrenia 18–65 years Chronic, not treatment 
resistant, in- and 
outpatients, discontinued 
Perphenazine
115/114/37 18 months IndependentBMC Psychiatry 2008, 8:31 http://www.biomedcentral.com/1471-244X/8/31
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Swartz et al. 
[38]
Olanzapine
Perphenazine
Quetiapine
Risperidone
Ziprasidone
Not disclosed
-
-
-
-
Schizophrenia 18–65 years Chronic, not treatment 
resistant, in- and 
outpatients
1493/985/455 18 months Independent
Tunis et al. 
[39]
Olanzapine
Risperidone
Haloperidol
Perphenazine
13.5 mg (1.35)
4.9 mg (0.99)
11.0 mg (1.37)
14.2 mg (0.47)
Schizophrenia, 
schizoaffective- 
schizophrenifor
m disorder, ≥ 
18 on the BPRS
≥ 18 years Primarily outpatients 664/-/455 12 months Eli Lilly 
company
Abbreviations: Comparators = Antipsychotics being compared in the studies; Doses = Mean daily doses of the antipsychotics; DDD = Defined Daily Doses of the 
antipsychotics; Diagnoses = Diagnoses defined in inclusion criteria; Age = Age of study participants; Phase = Phase of psychotic illness of study participants: acute or chronic; 
Status = Status of study participants: first episode, inpatients, outpatients; N0 = Number of participants at baseline; Nitt = Number in intention to treat group (not disclosed in 
all studies as indicated by (-)), N1 = Number of completers; Follow-up = Duration of study follow-up; Funding = Financial support of study; BMS = Bristol-Myers Squibb; 
Otsuka = Otsuka America Pharmaceuticals, inc.; Independent = Study financially supported by sources independent of the pharmaceutical industry. A = Aripiprazole, FGAs = 
First generation antipsychotics, H = Haloperidol, O = Olanzapine, P = Perphenazine, Q = Quetiapine, R = Risperidone, Z = Ziprasidone, BPRS = the Brief Psychiatric Rating 
Scale, d = depot formulation.
1 Mean maximum daily dosage
2 Schizophrenia, schizophreniform -, schizoaffective -, delusional disorder, major depressive disorder with psychotic features, Alzheimer's dementia with psychotic symptoms, 
vascular dementia, dementia due to substance abuse
Table 1: Methodology (Continued)
studies [27,32-34,39], whereas one study found equal
effectiveness among the comparators [25].
Discussion
In this literature search 16 reports were located with com-
parisons of SGAs in clinical settings, and performed with
the basic methodological demands such as randomiza-
tion fulfilled. With regards to global outcomes the most
consistent finding was a superior drug adherence or time
to treatment discontinuation (drug survival) for olanzap-
ine in patients suffering from chronic schizophrenia. Drug
adherence and survival were considered global effective-
ness outcome measures, as they were thought to reflect
both efficacy and tolerability of the drugs as judged by
both the patient and treating psychiatrist. The outcome
measure is clinically important, as antipsychotic drug
adherence has major influences on risks of relapse, rehos-
pitalisation and suicide in patients with schizophrenia
[40]. Three of the five studies using this outcome measure
were from the CATIE trial. A critical question is whether
the comparator drugs were used in equivalent doses in the
CATIE studies [41]. To permit blinding combined with
flexible-dose regimens in the CATIE study, drug doses rep-
resenting a quartile of the maximal daily drug dose were
packaged in 4 capsules that were identical-appearing for
all study drugs. The matter of choice of upper dose limit
has substantial impact upon the individual steps in the
up-titration of the drugs. The upper dose limit for olanza-
pine is, in contrast to the other drugs, set above the label-
defined upper dosage limit of 20 mg [31]. This causes big-
ger up-titration steps for olanzapine than the compara-
tors, as each up-titration step correlates with more
"response" for olanzapine compared to the other drugs
under investigation. The fact that the studies by Jerrel [30]
and Tunis et al. [39] have similar results to the ones from
the CATIE despite the use of lower doses of olanzapine
supports the finding of superiority of olanzapine on treat-
ment adherence, however.
Regarding ability to alleviate symptoms of psychosis, the
drugs performed equally in all acute phase studies and all
but one chronic phase studies. The solitary CATIE study
that found olanzapine to be superior to quetiapine and
ziprasidone had a sample of chronic schizophrenia
patients that had previously discontinued an SGA because
of intolerability. In this study the mean DDD of olanzap-
ine was 2.05 compared to 1.41 and 1.45 for quetiapine
and ziprasidone respectively. The difference in total
PANSS response may in line with the above mentioned
argument be a result of non-equivalent doses. In the study
by Tunis et al. [39] olanzapine had more clinical
responder days compared to risperidone, as defined by
mean number of days with scores of the Brief Psychiatric
Rating Scale (BPRS) less than 18. This finding does not
necessarily imply that the olanzapine group was more
effective than the risperidone group as measured by total
reduction of BPRS. The latter comparison is not disclosed
in the paper.
The tolerability outcomes were somewhat surprising as
the SGAs performed equally on most measures. Maybe
the most striking finding was the lack of differences
between the SGAs with regard to the extrapyramidal syn-
drome and related side effects across all studies. This
might indicate that the drugs' distinct side effect profiles
derived from efficacy trials are "levelled out" at least to
some degree in the naturalistic setting where samples are
more heterogeneous and concomitant psychotropics are
less restricted. It is worth noting that some of the studies
have rather low sample sizes, which increases the risk of
statistical type 2 errors and thereby failure to detect real
differences between drugs. The most pronounced differ-
ence between the SGAs was in the area of metabolic
adverse effects, where olanzapine-treated patients gained
more weight and had the most adverse influence on cho-
lesterol and triglycerides levels.BMC Psychiatry 2008, 8:31 http://www.biomedcentral.com/1471-244X/8/31
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Table 2: Global outcomes
Studies Main results (outcome measures)
FIRST EPISODE
Crespo-Facorro et al. 
[24]
No global outcomes
McEvoy et al. [25] O = Q = R (time to discontinuation for any cause, for inadequate therapeutic effect, for unacceptable side effects, for patients 
decision)
Robinson et al. [26] O = R (rate of discontinued intervention)
ACUTE PHASE
Chrzanowski et al. [27] No global outcomes
Kraus et al. [28] O = R (Duration of hospitalisation)
McCue et al. [29] H = O = R > A = Q = Z (no longer needing acute in-patient care)(p < 0.0001)
A = H = O = Q = R = Z (time until treatment classified as effective, i.e. no longer needing acute in-patient care, medication 
ineffective as judged by discontinuation because of no significant improvement after at least 3 weeks of treatment, side-effects or 
significant deterioration of patient's mental state.)
CHRONIC PHASE
Jerrel [30] O (p = 0.02) & R (p = 0.005) > FGA (total mental health treatment costs)1
O > R & FGA (odds of compliance) (p < 0.001)
O = R = FGA (psychosocial functioning (RFS), time to discharge and rehospitalisation, client satisfaction (CSQ)).
Lieberman et al. [31] O > Q (p < 0.001) & R (p = 0.002) (Time to discontinuation for any cause)
O > P (p < 0,001) = Q (p < 0.001) = R (p < 0.001) (Time to discontinuation for lack of efficacy)
O = Q = P = R = Z (Time to discontinuation for intolerable side effects)
O > Q (p < 0.001) = R (p = 0.008) (time to discontinuation due to patient's decision)
Q > Z > P > R > O (p < 0.001) (hospitalisation for exacerbation of schizophrenia)
Mullen et al. [32] No global outcomes
Ritchie et al. [33] O = R (quality of life, except O > R for psychological well-being (p = 0.02)
Ritchie et al. [34] O > R (physical health (p = 0.03), social relationships (p = 0.015); overall quality of life (p = 0.04), health satisfaction (p = 0.03))
O = R (psychological well-being, environmental domain)
Rosenheck et al. [35] O = Q = R = Z > P (total health care costs) (p < 0.001)
O & Q & R & Z > P (total medication costs) (p < 0.0001)
O > Q & R & Z (drug costs) (p = ?)
P > R (Quality Adjusted Life Years ratings) (p < 0.005)
O = P = Q = R = Z (quality of life measures)
Stroup et al. [36] O = R > Q (p < 0.05) = Z (p < 0.01) (time to discontinuation for any cause)
O = Q = R = Z (time to discontinuation for lack of efficacy/for intolerable side effects)
O > Q = Z (time to discontinuation for patients who previously discontinued SGA due to inefficacy) (p < 0.01)
R > Q (time to discontinuation for patients who previously discontinued SGA due to inefficacy) (p < 0.05)
Q > Z > R > O (p = 0.02) (hospitalisation for exacerbation of schizophrenia)
Stroup et al. [37] O (p = 0.02) = Q (p = 0.04) > R (Time to discontinuation for all causes)
O = Q = R (cause of discontinuation)
Swartz et al. [38] O = P = Q = R = Z (change in the Quality of life total and subscores at 6, 12 and 18 months)
Tunis et al. [39] O = R = FGAs (total costs)
O > R & FGA (antipsychotic costs) (p < 0.001)
R (p < 0.001) > FGA (p < 0.001) > O(rate of switching from assigned antipsychotic agent)
O > R (p = 0.002) & FGA (p = 0.043) (mean social responder days2)
Abbreviations: A = Aripiprazole, FGAs = First generation antipsychotics, H = Haloperidol, O = Olanzapine, P = Perphenazine, Q = Quetiapine, R 
= Risperidone, Z = Ziprasidone CSQ-8 = the Client Satisfaction Questionaire-8; RFS = the Role Functioning Scale
1 Total mental health treatment costs: Inpatient, outpatient and psychiatric medication costs.
2 Social response is defined as maintaining a high level of satisfaction with social relationships (for patients reporting a baseline score of at least 18), 
or by improving at least 33% of possible improvement.
? = The authors state that the difference is significant, but do not reveal the p-value for this comparison.BMC Psychiatry 2008, 8:31 http://www.biomedcentral.com/1471-244X/8/31
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Six studies included a FGA arm in the design and two of
these studies found the FGA(s) to be associated with lower
total mental health care costs [30,35], whereas one study
found equal total costs between olanzapine, risperidone
and the FGAs haloperidol and perphenazine [39]. The lat-
ter study was supported by industry. Cost-effectiveness
measurements were not included in the rest of the studies.
Based on the present review the SGAs were not superior to
FGAs with regards to treating symptoms of disease. The
FGAs were associated with more EPS and related adverse
effects in 3 of the studies involving a FGA arm, however.
Important factors not reviewed in the present paper
include the potential differential effects of SGAs versus
FGAs on cognitive impairments and risk of relapse. There
Table 3: Symptoms of disease
Studies Main results (rating scales/outcome measures)
FIRST EPISODE
Crespo-Facorro et al. [24] O = R = H (CGI-S, BPRS, SAPS, SANS, HAM-D, CDS, YMRS, response1 rate, mean time to response)
McEvoy et al. [25] O = Q = R (PANSS total change)
O > Q (PANSS positive subscale reduction) (p = 0.013)
O = Q = R (response rate2)
Robinson et al. [26] O = R (cumulative response3rates, mean time to response)
O = R (delusions, hallusinations, thought disorders (SADS-C+PD positive symptoms items); affective flattening, alogia, 
avolition-apathy, asociality-anhedonia (SANS))
R > O (mean length of time that subjects maintained the of responder status) (CI= 8.6-10.4 vs. 5.6-7.7)
ACUTE PHASE
Chrzanowski et al. [27] A = O (PANSS, CGI-I)
Kraus et al. [28] No outcomes
McCue et al. [29] A = H = O = Q = R = Z (BPRS change)
CHRONIC PHASE
Jerrel [30] O = R = FGA (PANSS, BPRS, DIS-III-R Depression and Mania symptoms)
Lieberman et al. [31] O = P = Q = R = Z (PANSS, CGI)
O > Q (p < 0.001) & R (p = 0.002) & P (p = 0.013) (duration of successful treatment4)
R > Q (duration of successful treatment) (p = 002)
Mullen et al. [32] Q = R (PANSS)
Q > R (HAM-D) (p = 0.028)
Q = R (CGI-I)
Ritchie et al. [33] O = R (BPRS, SANS, MADRS, MMSE)
Ritchie et al. [34] O = R (BPRS, SANS, MADRS, MMSE)
Rosenheck et al. [35] O = P = Q = R = Z (PANSS)
Stroup et al. [36] O > Q (p = 0.005) & Z (p = 0.005) (PANSS)
O > Q (p < 0.001) & Z (p < 0.001) & R (p < 0.02) (PANSS positive symptoms)
R > Z (p < 0.03) (PANSS positive symptoms)
O = Q = R = Z (CGI)
Stroup et al. [37] O = Q = R (PANSS)
O = Q = R (CGI at endpoint)
Swartz et al. [38] No outcomes
Tunis et al. [39] O > FGA (mean clinical responder days5) (p = 0.025)
Abbreviations: A = Aripiprazole, FGAs = First generation antipsychotics, O = Olanzapine, P = Perphenazine, Q = Quetiapine, R = Risperidone, Z 
= Ziprasidone, CGI-I = Clinical Global Improvement Scale, CGI = CGI-S = Clinical Global Impressions- Severety of Illness Scale, PANSS = the 
Positive And Negative Syndrome Scale, BPRS = the Brief Psychiatric Rating Scale, SAPS = the Scale for the Assessment of Positive Symptoms, SANS 
= the Scale for the Assessment of Negative Symptoms, DIS-III-R = Diagnostic Interview Schedule III-R Depression and Mania Modules, HAM-D = 
the Hamilton Rating Scale for Depression, MADRS = the Montgomery Åsberg Depression Rating Scale, MMSE = Mini-mental state examination.
1 Response = 40% or greater BPRS total improvement from baseline.
2Response = ≤ 3 for all PANSS items and = 3 for the CGI-S.
3 Response = mild or better on SADS-C+PD positive symptoms items plus CGI much or very much improved.
4 Successful treatment time is defined as number of months of treatment in which patients had a CGI Scale score of at least 3 or a score of 4 with 
an improvement of at least two points from baseline.
5 Clinical response is defined as a BPRS score less than 18.
Subanalyses on efficacy measures are omitted
[24], [25] and [27] provide analyses on both last observation carried forward (LOCF) and observed cases. The main findings are the same, but only 
p-values for LOCF data are displayed in the table.BMC Psychiatry 2008, 8:31 http://www.biomedcentral.com/1471-244X/8/31
Page 9 of 14
(page number not for citation purposes)
Table 4: Tolerability outcomes (rating scales/outcome measures)
Studies Main results
FIRST EPISODE
Crespo-Facorro et al. [24] O = H = R (AIMS)
O = H = R (asthenia, tremor, increased/reduced salivation, erectile and ejaculatory dysfunction, amenorrhoea (UKU))
H > O & R (treatment emergent parkinsonism (SAS) (p < 0.001) and akathisia (BARS) (p < 0.001))
H > O > R (concentration difficulties (p = 0.044), sleepiness/sedation (0.012) increased duration of sleep (p = 0.033) (UKU))
H > R > O (rigidity (p = 0.005), hypokinesia (p = 0.006), akathisia (p = 0.029) (UKU))
O > R > H (weight gain) (p < 0.001) (UKU)
McEvoy et al. [25] O = Q = R (SAS, BARS, AIMS)
O > Q & R(weight gain and BMI change, and male weight gain and BMI change) (p < 0.01)
O > Q (female weight gain and BMI change) (p < 0.001)
R > Q (female weight gain and BMI change) (p < 0.01)
Q & R < O (weight gain > 7 %) (p < 0.05)
O > Q (male weight gain > 7 % (week 12 only)) (p < 0.01)
O > R (male weight gain > 7 %) (p < 0.05)
O > Q (female weight gain > 7% (week 12 only)) (p < 0.01)
R > Q (female weight gain > 7 % (week 52 only)) (p < 0.05)
O > Q (BMI increase ≥ 1 unit) (p < 0.05)
O > R (BMI increase ≥ 1 unit (week 12 only)) (p < 0.01)
O > Q (male BMI increase ≥ 1 unit (week 12 only)) (p < 0.05)
O > R (male BMI increase ≥ 1 unit) (p < 0.05)
O > Q (female BMI increase ≥ 1 unit (week 12 only)) (p < 0.01)
O > R (female BMI increase ≥ 1 unit (week 12 only)) (p < 0.05)
O > R (female waist circumference > 35 inches change (week 12 only)) (p < 0.05)
O & Q > R ((fasting TG levels change (week 52 only) (p < 0.05)
Q > R (increase of proportion with fasting TG level > 150 mg/dl) (p < 0.01)
Q > O (increase of proportion with fasting TG level > 150 mg/dl (week 12 only)) (p < 0.05)
Q > R (fasting total cholesterol change (week 52 only)) (p < 0.05)
O > Q (negative fasting HDL cholesterol change and male negative fasting HDL cholesterol change (week 52 only)) (p < 0.05)
O > R (negative fasting HDL cholesterol change) (p < 0.05)
O > R (male negative fasting HDL cholesterol change (week 52 only)) (p < 0.05)
R > O & Q (prolactin level change) (p < 0.001)
Q > R (systolic blood pressure increase) (p < 0.01)
O > R (systolic blood pressure increase) (p < 0.05)
O > R (diastolic blood pressure increase (week 52 only)) (p < 0.05)
O > R (increase of proportion with systolic blood pressure ≥ 130 mm Hg (week 52 only)) (p < 0.05)
Q > R (increase of proportion with diastolic blood pressure ≥ 85 mm Hg (week 52 only)) (p < 0.05)
Robinson et al. [26] O = R (SAS, BARS)
O > R (weight gain) (p < 0.01)
ACUTE PHASE
Chrzanowski et al. [27] A = O (insomnia, anxiety, headache, somnolence, infection, nervousness, akathisia, schizophrenic reaction, flu syndrome, CNS 
stimulation, lightheadedness, tremor, SAS, BARS, AIMS, triglyceride change)
O > A (Weight gain (p < 0.001, Weight gain > 7% (p = 0.008), elevated total (p < 0.01) and LDL cholesterol (p < 0.01), 
negative influence on HDL cholesterol (p < 0.05), QTc prolongation (p = 0.008), prolactin elevation (p < 0.001)
Kraus et al. [28] No outcomes
McCue et al. [29] A = H = O = Q = R = Z (SAS, BARS, spontaneous reports of adverse events)
A = H = O = Q = R = Z (withdrawals because of side-effects)
CHRONIC PHASE
Jerrel [30] O = R = FGA (DISCUS, SAS, BARS)BMC Psychiatry 2008, 8:31 http://www.biomedcentral.com/1471-244X/8/31
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are some indications that SGAs are superior to FGAs on
these outcome measures [42,43]. Before these issues are
further investigated in effectiveness studies it would be
premature to properly estimate cost-benefit of the drugs.
One third of the studies were funded by the pharmaceuti-
cal industry and in these studies main findings of differ-
ences between the SGAs were in favour of the funder's
product in 5 of 6 cases. In recent years the matter of con-
Lieberman et al. [31] O = P = Q = R = Z (any moderate or severe adverse effect, suicide attempt or ideation, hypersomnia, sleepiness, decreased 
sex drive, arousal, ability to reach orgasm, gynecomastia, galactorrhoea, menstrual irregularities, orthostatic faintness, AIMS, 
BARS, SAS, discontinuation owing to sedation, change from baseline of blood glucose, change in corrected QT interval, new 
cataracts)
O > Q > R > P > Z (weight gain > 7%, mean cholesterol and -triglyceride change) (p < 0.001); (meanHbA1c change) (p = 
0.01)
O > Q > R > Z* > P* (weight change) (p < 0.001)
O > Z > P > R > Q (HbA1c change) (p = 0.01)
O > Q > P > R* > Z* (cholesterol change, triglyceride change) (p < 0.001)
O > Q > Z > R > P (discontinuation owing to weight gain or metabolic effects) (p < 0.001)
O > Q = P = Z > R (discontinuation owing to intolerability) (p = 0.04)
Q > R > O > P > Z (urinary hesitancy, dry mouth, constipation) (p < 0.001)
Z > P > R > Q > O (insomnia) (p < 0.001)
R > O = Z > Q > P (incontinence, nocturi) (p = 0.04)
P > Z > Q = R > O (discontinuation owing to EPS) (p = 0.002)
R > P > >Z > O > Q (mean prolactin change)(p < 0.001)
Q & R > O & Z (prolonged QTc interval) (p < 0.03)
Mullen et al. [32] Q = R (EPS total (EPS checklist), odds of having an EPS event)
R > Q (for odds of EPS of at least moderate severity (p = 0.03), odds of substantial EPS (p < 0.001), requirement of anti- EPS 
medication during the trial among baseline EPS patients (p < 0.001)
Q > R (somnolence, dry mouth, dizziness, agitation) (p < 0.05)
Ritchie et al. [33] O = R (SAS, AIMS, BARS, specific side effects)
Ritchie et al. [34] O = R (SAS, AIMS, BARS, sedation, hypotension, dizziness, gastrointestinal side effects, libido, anticholinergics symptoms, weight 
gain)
Rosenheck et al. [35] No outcomes
Stroup et al. [36] O = Q = R = Z (hypersomnia, sleepiness, urinary hesitancy/dry mouth/constipation, incontinence/nocturia, AIMS, BARS, SAS, 
discontinuation because of intolerable extrapyramidal side effects or sedation, weight change over course of treatment, change 
of blood glucose and HbA1c, change in QTc interval)
O > Q = R > Z (> 7% weight gain) (p = 0.009)
O > Q > R* > Z * (average change in weigh and cholesterol change) (p < 0.001)
O > Q > Z* > R* (mean change in triglycerides) (p < 0.001)
Q > O > R > Z (orthostatic faintness) (p < 0.05);discontinuation because of intolerable weight or metabolic side effects) (p = 
0.004)
Q > R > Z > O (skin rash) (p < 0.05)
Q > Z > O > R (any spontaneous report of moderate/severe adverse effect) (p < 0.02))
R > O > Z > Q (adverse events related to sex drive/sexual arousal/sexual orgasm) (p < 0.05)
R > O = Z > Q (gynecomastia/galactorrhoea) (p < 0.04)
R > Z* > O* > Q* (change of prolactin level) (p < 0.001)
Z > R > Q > O (any serious adverse event) (p = 0.01)
Z > R >Q > O (insomnia) (p < 0.001)
Stroup et al. [37] O = Q = R (any moderate, severe or serious adverse event, insomnia, hypersomnia, sleepiness, urinary hesitancy, dry mouth, 
constipation, decreased sexual drive, sexual arousal, orgasm, incontinence, nocturia, sialorrhoea, orthostatic faintness, skin rash, 
AIMS, weight gain > 7%, rate of weight gain, change of blood glucose, HbA1c, QTc interval)
O > Q > R (amount of weight gain) (p = 0.005;, (triglyceride change) (p = 0.03)
O > R > Q (total cholesterol change) (p = 0.01)
R > Q* > O* (change of prolactin level) (p < 0.001)
Swartz et al. [38] No outcomes
Tunis et al. [39] O = R = FGAS (any serious AE)
O > FGA (probability of not developing EPS over 1 year among those without EPS at baseline) (p = 0.006)
R (p = 0.023) & FGAs (p < 0.0001) > O (time to 7% weight gain)
O > R > FGA (weight gain for patients on initial antipsychotic regimen) (significant1, p = ?)
Abbreviations: A = Aripiprazole, FGAs = First generation antipsychotics, O = Olanzapine, P = Perphenazine, Q = Quetiapine, R = Risperidone, Z 
= Ziprasidone, DISCUS = the Dyskinesia Identification System Condensed User Scale, BARS = Barnes Akathisia Scale, AIMS = the Abnormal 
Involuntary Movement Scale, BARS = the Barnes Akathisia Rating Scale, SAS = the Simpson Angus Scale, UKU = UKU Side Effect Rating Scale, EPS 
= the extrapyramidal syndrome, BMI = Body Mass Index.
* = negative change
1 The authors state that the difference is significant, but do not reveal the p-value for this comparison.
[24], [25] and [27] provide analyses on both last observation carried forward (LOCF) and observed cases. The main findings are the same, but only 
p-values for LOCF data are displayed in the table.
Table 4: Tolerability outcomes (rating scales/outcome measures) (Continued)BMC Psychiatry 2008, 8:31 http://www.biomedcentral.com/1471-244X/8/31
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flict of interest in research has become a major concern as
a high number of psychotropic drug trials are financially
supported by the industry, and "funding bias" has been
pin-pointed by several authors [44-49]. In a review of
head-to-head RCT comparisons of SGAs, outcomes were
in favour of the funding party in 9 out of 10 studies, which
also led to contradictory results in studies from different
sources of sponsorship [50]. In a recent meta-analysis by
Davis et al. [51] on the efficacy of SGAs, the conclusion is
that some of the SGAs are more efficacious than others
when compared to FGAs. Davis et al. state that almost all
the studies in their analysis were supported by industry. In
the SGA vs. FGA comparisons it is reasonable to presume
without exception that the FGAs are the reference drugs
and that sponsorships are strongly associated with the
SGAs. Interestingly, the SGAs with the highest effect sizes
were also the ones represented with the largest number of
studies (Figure 1). In fact, there seems to be an almost lin-
ear relationship between number of studies on, and effect
sizes for individual SGAs, with remoxipride being the only
deviator. If there is a systematic bias that favours the drug
of the funding party, this could at least in part explain the
obvious "dose-response" relationships observed in Figure
1, with number of studies being the "dose" and effect size
being the "response". Results from both efficacy and effec-
tiveness studies funded by the pharmaceutical industry
should accordingly be interpreted bearing the possibility
of "funding bias" in mind.
The present sixteen studies were all performed according
to naturalistic designs. However, certain methodological
differences reflect that the concepts of effectiveness trials
and of naturalistic/real life/pragmatic/practical
approaches are not strictly defined. There are obvious dif-
ferences between the studies' samples (Table 1). This fact
makes it very dubious to pool the rates from individual
Table 5: Concomitant medication
Studies Comparators
FIRST EPISODE
Crespo-Facorro et al. [24] H = O = R (benzodiazepines for anxiety/agitation or EPS; hypnotics)
H > R > O (anticholinergics for EPS) (p < 0.0001)
McEvoy et al. [25] O = Q = R (postbaseline adjunctive medication use for dysphoria/depression, anxiety, insomnia, agitation/excitement)
O > Q (proportion receiving concomitant medications for parkinsonism or akathisia) (p = 0.021)
Robinson et al. [26] O = R (divalproex, sertraline, benztropin, propranolol, lorazepam)
ACUTE PHASE
Chrzanowski et al. [27] A = O (anticholinergics)
Kraus et al.* [28] O = R (benztropine and/or trihexyphenidyl, mood-stabilizers, antidepressants, haloperidol, quetiapine, ziprasidone, 
perphenazine, lorazepam and/or clonazepam)
R > O (diphenhydramine and/or hydroxyzine) (p = 0.05)
McCue et al. * [29] A = H = O = Q = R = Z (dosages of additional: haloperidol, lorazepam, benzatropine)
A = H = O = Q = R = Z (patients receiving additional: mood stabiliser, antidepressant, anxiolytic)
A > Q > R > Z > H > O (dosage of diphenhydramine) (p = 0.004)
H > R > Q = Z > A = O (patients receiving anticholinergics) (p < 0.0001)
CHRONIC PHASE
Jerrel * [30] O & R > FGA (odds of being prescribed mood-stabilizers or supplemental antipsychotics) (p < 0.001)
Lieberman et al. [31] O = P = Q = R = Z (lithium, anticonvulsants, oral glucose-lowering drugs, insulin, cholestatin drugs)
R > Z > O > P > Q (antidepressants) (p = 0.03)
R = P = Z > O > Q (hypnotics, sedatives) (p = 0.03)
P = Z > Q > R > O (anxiolytics) (p < 0.001)
P > R > Z > O > Q (anticholinergics agents) (p = 0.01)
Mullen et al.* [32] Not disclosed
Ritchie et al. [33] Not disclosed
Ritchie et al. [34] Not disclosed
Rosenheck et al. [35] Not disclosed
Stroup et al. [36] O = Q = R = Z (details not disclosed)
Stroup et al. [37] O = Q = R (lithium, anticonvulsants, antidepressants, hypnotic, sedatives, anxiolytics, anticholinergics, oral glucose-lowering 
drugs and insulin, cholestatin drugs)
Swartz et al. [38] Not disclosed
Tunis et al. [39] Details not disclosed
Abbreviations: A = Aripiprazole, FGAs = First generation antipsychotics, O = Olanzapine, P = Perphenazine, Q = Quetiapine, R = Risperidone, Z 
= Ziprasidone, EPS = the extrapyramidal syndrome, * = Additional antipsychotics permitted.BMC Psychiatry 2008, 8:31 http://www.biomedcentral.com/1471-244X/8/31
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studies in meta-analyses and for instance calculate joint
effect-sizes ("the apples and oranges error) [52]. To bypass
this source of bias, we presented the main results from
each study separately and with emphasis on statistically
significant differences between the SGAs excluding abso-
lute figures or rates. This of course represents a crude
method but is well suited in search of robust differences
between the SGAs. Four studies permitted the use of addi-
tional antipsychotics which could confound comparisons
between the SGAs [28-30,32]. No differences were found
between the SGAs in the use of supplemental antipsychot-
ics, however. Another limitation of this review is that only
3 studies included first-episode patients of which 1 study
was of very short duration. From a clinical point of view,
the first-time antipsychotic intervention is the one associ-
ated with the highest degree of uncertainty. In the chronic
patient, prior experience with antipsychotics may deliver
valuable information in the decision making about
choosing an antipsychotic drug. For the drug-naïve, phy-
sicians are forced to perform sometimes extensive drug
"trials" in the individual patient before an antipsychotic
drug with satisfying effect profile is identified. Besides the
economical aspects and the strain on the patient, this
"trial" approach that may take several months extends the
duration of untreated psychosis which may be a negative
prognostic factor. More effectiveness studies on first-epi-
sode patients and with longer follow-up are called for.
Conclusion
Despite the limitations mentioned above we conclude
that in chronically ill patients olanzapine may have an
advantage over other SGAs regarding longer time to treat-
ment discontinuation and a better drug adherence, but
olanzapine is also associated with more metabolic side
effects. The SGAs were equally associated with EPS and
related side effects.
More studies on first-episode psychosis are needed.
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
EJ did the literature search and drafted the manuscript.
HAJ participated in the design of the review and helped to
draft the manuscript. Both authors read and approved the
final manuscript.
Acknowledgements
The authors wish to thank statistician Tore Wentzel-Larsen at the Centre 
for Clinical Research, Haukeland University Hospital for statistical advice.
References
1. American Psychiatric Association: Practice guidelines for the
treatment of patients with schizophrenia.  Edited by: Arlington
VA. American Psychiatric Association; 2004. 
2. Marder SR, Essock SM, Miller AL, Buchanan RW, Davis JM, Kane JM,
Lieberman J, Schooler NR: The Mount Sinai conference on the
pharmacotherapy of schizophrenia.  Schiz Bull 2002, 28(1):5-16.
3. Moore TA, Buchanan RW, Buckley PF, Chiles JA, Conley RR, Crismon
ML, Essock SM, Finnerty M, Marder SR, Miller del D, McEvoy JP, Rob-
inson DG, Schooler NR, Shon SP, Stroup TS, Miller AL: The Texas
medication algorithm project antipsychotic algorithm for
schizophrenia: 2006 update.  J Clin Psychiatry 2007,
68(11):1751-62.
4. National Institute for Clinical Excellence: Guidance on the use of
newer (atypical) antipsychotic drugs for the treatment of
schizophrenia.  Technology appraisal guidance – No.43 2002 [http://
www.nice.org.uk].
5. Bagnall A, Kleijnen J, Leitner M, Lewis R: Ziprasidone for schizo-
phrenia and severe mental illness.  Cochrane Database of System-
atic Reviews 2000:Art. No.: CD001945. DOI: 10.1002/
14651858.CD001945
6. Duggan L, Fenton M, Rathbone J, Dardennes R, El-Dosoky A, Indran
S: Olanzapine for schizophrenia.  Cochrane Database of Systematic
Reviews 2005:Art. No.: CD001359. DOI: 10.1002/
14651858.CD001359.pub2
7. El-Sayeh HG, Morganti C: Aripiprazole for schizophrenia.
Cochrane Database of Systematic Reviews 2006:Art. No.: CD004578.
DOI: 10.1002/14651858.CD004578.pub3
8. Gilbody SM, Bagnall AM, Duggan L, Tuunainen A: Risperidone ver-
sus other atypical antipsychotic medication for schizophre-
nia.  Cochrane Database of Systematic Reviews 2000:Art. No.:
CD002306. DOI: 10.1002/14651858.CD002306
9. DeSilva P, Fenton M, Rathbone J: Zotepine for schizophrenia.
Cochrane Database of Systematic Reviews 2006:Art. No.: CD001948.
DOI: 10.1002/14651858.CD001948.pub2.
10. Rummel C, Hamann J, Kissling W, Leucht S: New generation antip-
sychotics for first episode schizophrenia.  Cochrane Database of
Systematic Reviews 2003:Art. No.: CD004410. DOI: 10.1002/
14651858.CD004410
11. Srisurapanont M, Maneeton B, Maneeton N: Quetiapine for schiz-
ophrenia.  Cochrane Database of Systematic Reviews 2004:Art. No.:
CD000967. DOI: 10.1002/14651858.CD000967.pub2
Effect sizes of second generation antipsychotics compared  with first generation antipsychotics Figure 1
Effect sizes of second generation antipsychotics com-
pared with first generation antipsychotics. Relationship 
between number of studies on the individual drugs, and effect 
sizes of the respective 10 second generation antipsychotics 
compared to first generation antipsychotics. Adapted from 
Table 2 in Davis et al. [44]
5 1 01 52 02 53 0
-
0
.
1
0
.
0
0
.
1
0
.
2
0
.
3
0
.
4
0
.
5
Number of studies
E
f
f
e
c
t
 
s
i
z
eBMC Psychiatry 2008, 8:31 http://www.biomedcentral.com/1471-244X/8/31
Page 13 of 14
(page number not for citation purposes)
12. Tuunainen A, Wahlbeck K, Gilbody SM: Newer atypical antipsy-
chotic medication versus clozapine for schizophrenia.
Cochrane Database of Systematic Reviews 2000:Art. No.: CD000966.
DOI: 10.1002/14651858.CD000966
13. Rosenheck R, Perlick D, Bingham S, Liu-Mares W, Collins J, Warren
S, Leslie D, Allan E, Campbell EC, Caroff S, Corwin J, Davis L, Douyon
R, Dunn L, Evans D, Freeska E, Grabowski J, Graaeber D, Herz L,
Kwon K, Lawson W, Mena F, Sheikh J, Smelson D, Smith-Gamble V:
Effectiveness and cost of Olanzapine and haloperidol in the
treatment of schizophrenia.  JAMA 2003, 290(20):2693-2702.
14. Bowen J, Hirsch S: Recruitment rates and factors affecting
recruitments for a clinical trial of a putative anti-psychotic
agent in the treatment of acute schizophrenia.  Hum Psychop-
harmacol 1992, 7:337-41.
15. Robinson D, Woerner M, Pollack S, Lerner G: Subject selection
biases in clinical trials: Data from a multicenter schizophre-
nia treatment study.  J Clin Psychopharmacol 1996, 16(2):170-6.
16. Hofer A, Hummer M, Huber R, Kurz M, Walch T, Fleischhacker WW:
Selection bias in clinical trials with antipsychotics.  J Clin Psy-
chopharmacol 2000, 20(6):699-702.
17. Johnsen E, Svingen GF, Jørgensen HA: Practice regarding antipsy-
chotic therapy: A cross-sectional survey in two Norwegian
hospitals.  Nord J Psychiatry 2004, 58:313-317.
18. Martin K, Bègaud B, Verdoux H, Lechevallier N, Latry P, Moore N:
Patterns of risperidone prescription: a utlilization study in
south-west France.  Acta Psychiatr Scand 2004, 109:202-6.
19. Ganguli R, Kotzan JA, Miller LS, Kennedy K, Martin DM: Prevalence,
trends, and factors associated with antipsychotic polyphar-
macy among Medicaid-eligible schizophrenia patients, 1998–
2000.  J Clin Psychiatry 2004, 65:1377-88.
20. Edlinger M, Hausmann A, Kemmler G, Kurz M, Kurzhaler I, Walch T,
Walpoth M, Fleischhacker WW: Trends in the pharmacological
treatment of patients with schizophrenia over a 12 year
observation period.  Schizophr Res 2005, 77:25-34.
21. Jaffe AB, Levine J: Efficacy and effectiveness of first- and second-
generation antipsychotics in schizophrenia.  J Clin Psychiatry
2003, 64(suppl 17):3-6.
22. Nasrallah HA, Targum SD, Tandon R, McCombs JS, Ross R: Defining
and measuring clinical effectiveness in the treatment of
schizophrenia.  Psychiat Serv 2005, 56:273-82.
23. American Psychiatric Association: Practice guideling for the
treatment of patients with major depressive disorder.  2nd
edition. Edited by: Arlington VA. American Psychiatric association;
2000. 
24. Crespo-Facorro B, Pérez-Iglesias R, Ramirez-Bonilla M, Martinéz-
García O, LLorca J, Vásquez-Barquero JL: A practical clinical trial
comparing haloperidol, risperidone, and Olanzapine for the
acute treatment of first-episode nonaffective psychosis.  J Clin
Psychiatry 2006, 67:1511-21.
25. McEvoy JP, Lieberman JA, Perkins DO, Hamer RM, Gu H, Lazarus A,
Sweitzer D, Olexy C, Weiden P, Strakowsky SD: Efficacy and tol-
erability of olanzapine, quetiapine, and risperidone in the
treatment of early psychosis: a randomized, double-blind 52-
week comparison.  Am J Psychiatry 2007, 164:1050-60.
26. Robinson DG, Woerner MG, Napolitano B, Patel RC, Sevy SM, Gun-
duz-Bruce H, Soto-Perello JM, Mendelowitz A, Khadivi A, Miller R,
McCormack J, Lorell BS, Lesser ML, Schooler NR, Kane JM: Rand-
omized comparison of Olanzapine versus risperidone for the
treatment of first-episode schizophrenia: 4-month out-
comes.  Am J Psychiatry 2006, 163:2096-2102.
27. Chrzanowski WK, Marcus RN, Torbeyns A, Nyilas M, McQuade RD:
Effectiveness of long-term aripiprazole therapy in patients
with acutely relapsing or chronic, stable schizophrenia: a 52-
week, open-label comparison with olanzapine.  Psychopharma-
cology 2006, 189:259-66.
28. Kraus JE, Sheitman BB, Cook A, Reviere R, Lieberman JA: Olanzap-
ine versus risperidone in newly admitted acutely ill psychotic
patients.  J Clin Psychiatry 2005, 66:1564-8.
29. McCue RE, Waheed R, Urcuyo L, Orendain G, Joseph MD, Charles
R, Hasan SM: Comparative effectiveness of second-generation
antipsychotics and haloperidol in acute schizophrenia.  Br J
Psychiatry 2006, 189:433-40.
30. Jerrel JM: Cost-effectiveness of risperidone, Olanzapine, and
conventional antipsychotic medications.  Schizophr Bull 2002,
28(4):589-605.
31. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Per-
kins DO, Keefe RSE, Davis SM, Davis CE, Lebowitz BD, Severe J,
Hsiao JK: Effectiveness of antipsychotic drugs in patients with
chronic schizophrenia.  N Engl J Med 2005, 355(12):1209-23.
32. Mullen J, Jibson MD, Sweitzer D: A comparison of the relative
safety, efficacy, and tolerability of quetiapine and risperidone
in outpatients with schizophrenia and other psychotic disor-
ders: The quetiapine experience with safety and tolerability
(QUEST) study.  Clin Ther 2001, 23:1839-54.
33. Ritchie CW, Chiu E, Harrigan S, Hall K, Hassett A, Macfarlane S, Mast-
wyk M, O'Connor DW, Opie J, Ames D: The impact upon extra-
pyramidal side effects, clinical symptoms and quality of life of
a switch from conventional to atypical antipsychotics (risp-
eridone or olanzapine) in elderly patients with schizophre-
nia.  Int J Geriatr Psychiatry 2003, 18:432-40.
34. Ritchie CW, Chiu E, Harrigan S, Macfarlane S, Mastwyk M, Halliday G,
Hustig H, Hall K, Hassett A, O'Connor DW, Opie J, Nagalingam V,
Snowdon J, Ames D: A comparison of the efficacy and safety of
olanzapine and risperidone in the treatment of elderly
patients with schizophrenia: an open study of six months
duration.  Int J Geriatr Psychiatry 2006, 21:171-9.
35. Rosenheck RA, Leslie DL, Sindelar J, Miller EA, Lin H, Stroup TS,
McEvoy J, Davis SM, Keefe RSE, Swartz M, Perkins DO, Hsiao JK, Lie-
berman J: Cost-effectiveness of second-generation antipsy-
chotics and perphenazine in a randomized trial of treatment
for chronic schizophrenia.  Am J Psychiatry 2006, 163:2080-9.
36. Stroup TS, Lieberman JA, McEvoy JP, Swartz MS, Davis SM, Rosen-
heck RA, Perkins DO, Keefe RSE, Davis CE, Severe J, Hsiao JK: Effec-
tiveness of olanzapine, quetiapine, risperidone, and
ziprasidone in patients with chronic schizophrenia following
discontinuation of a previous atypical antipsychotic.  Am J Psy-
chiatry 2006, 163:611-22.
37. Stroup TS, Lieberman JA, McEvoy JP, Swartz MS, Davis SM, Capuano
GA, Rosenheck RA, Keefe RSE, Miller AL, Belz JK: Effectiveness of
Olanzapine, quetiapine, and risperidone ion patients with
chronic schizophrenia after discontinuing perphenazine: A
CATIE study.  Am J Psychiatry 2007, 164:415-27.
38. Swartz MS, Perkins KO, Stroup TS, Davis SM, Capuano G, Rosenheck
RA, Reimherr F, McGee MF, Keefe RSE: Effects of antipsychotic
medications on psychosocial functioning in patients with
chronic schizophrenia: Findings from the NIMH CATIE
study.  Am J Psychiatry 2007, 164:428-36.
39. Tunis SL, Faries DE, Nyhuis AW, Kinon BJ, Ascher-Svanum H, Aquila
R: Cost-effectiveness of olanzapine as first-line treatment for
schizophrenia: Results from a randomized, open-label, 1-
year trial.  Value Health 2006, 9(2):77-89.
40. Leucht S, Heres S: Epidemiology, clinical consequences, and
psychosocial treatment of nonadherence in schizophrenia.  J
Clin Psychiatry 2006, 67(suppl 5):3-8.
41. Meltzer HY, Bobo WV: Interpreting the efficacy findings in the
CATIE study: What clinicians should know.  CNS Spectr 2006,
11(7 Suppl 7):14-24.
42. Keefe RSE, Silva SG, Perkins DO, Lieberman JA: The effects of
atypical antipsychotic drugs on neurocognitive impairment
in schizophrenia: a review and meta-analysis.  Schizophrenia Bull
1999, 25(2):201-22.
43. Leucht S, Barnes TRE, Kissling W, Engel RR, Correll C, Kane JM:
Relapse prevention in schizophrenia with new-generation
antipsychotics. A systematic review and exploratory meta-
analysis of randomized, controlled trials.  Am J Psychiatry 2003,
160:1209-22.
44. Perlis RH, Perlis CS, Wu Y, Hwang C, Joseph M, Nierenberg AA:
Industry sponsorship and financial conflict of interest in the
reporting of clinical trials in psychiatry.  Am J Psychiatry 2005,
162:1957-60.
45. Lexchin J, Bero LA, Djubegovic B, Clark O: Pharmaceutical indus-
try sponsorship and research outcome and quality: system-
atic review.  Br Med J 2003, 326:1-10.
46. Yaphe J, Edman R, Knishkowy B, Herman J: The association
between funding by commercial interests and study out-
come in randomized controlled trials.  Family practice 2001,
18(6):565-568.
47. Kjaergard LL, Als-Nielsen B: Association between competing
interests and authors' conclusions: epidemiological study of
randomized clinical trials in the BMJ.  Br Med J 2002,
325:249-252.Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
BMC Psychiatry 2008, 8:31 http://www.biomedcentral.com/1471-244X/8/31
Page 14 of 14
(page number not for citation purposes)
48. Clifford TJ, Barrowman NJ, Moher D: Funding source, trial out-
come and reporting quality: are they related. Results of a
pilot study.  BMC Health Serv Res 2002, 2(1):-18.
49. Djulbegovic B, Lacevic M, Cantor A, Fields K, Bennett CL, Adams JR,
Kuderer NM, Lyman GH: The uncertainty principle and indus-
try-sponsored research.  Lancet 2000, 356:635-638.
50. Heres S, Davis J, Maino K, Jetzinger E, Kissling W, Leucht S: Why
Olanzapine beats risperidone, risperidone beats quetiapine,
and quetiapine beats Olanzapine. An exploratory analysis of
head-to-head comparisons studies of second-generation
antipsychotics.  Am J Psychiatry 2006, 163:185-94.
51. Davis JM, Chen N, Glick ID: A meta-analysis of the efficacy of
second-generation antipsychotics.  Arch Gen Psychiatry 2003,
60:553-564.
52. Shirzadi AA, Ghaemi SN: Side effects of atypical antipsychotics:
extrapyramidal symptoms and the metabolic syndrome.
Harv Rev Psychiatry 2006, 14:152-64.
Pre-publication history
The pre-publication history for this paper can be accessed
here:
http://www.biomedcentral.com/1471-244X/8/31/pre
pub